Zomedica Corp. [AMEX: ZOM] loss -4.19% on the last trading session, reaching $0.09 price per share at the time. The company report on October 3, 2020 that Zomedica Announces Name Change.
Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020.
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
The Company’s board of directors approved the implementation of the name change following approval from the shareholders at the Annual General and Special Virtual-Only Meeting of shareholders held on September 25, 2020.
Zomedica Corp. represents 564.05 million in outstanding shares, while the company has a total market value of $49.50 million with the latest information. ZOM stock price has been found in the range of $0.09 to $0.09.
If compared to the average trading volume of 34.35M shares, ZOM reached a trading volume of 16264589 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Zomedica Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Corp. is set at 0.01 The Price to Book ratio for the last quarter was 1.09, with the Price to Cash per share for the same quarter was set at 0.05.
Trading performance analysis for ZOM stock
Zomedica Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.58. With this latest performance, ZOM shares dropped by -19.48% in over the last four-week period, additionally sinking by -35.22% over the last 6 months – not to mention a drop of -75.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 38.36, with the RSI for the last a single of trading hit 36.58, and the three-weeks RSI is set at 39.22 for Zomedica Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.1171, while it was recorded at 0.0908 for the last single week of trading, and 0.1842 for the last 200 days.
Zomedica Corp. [ZOM]: A deeper dive into fundamental analysis
Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.
Reflecting on the efficiency of the workforce at the company, Zomedica Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.30 and a Current Ratio set at 15.30.
Zomedica Corp. [ZOM]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Zomedica Corp. posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
An analysis of insider ownership at Zomedica Corp. [ZOM]
There are presently around $2 million, or 5.00% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. with ownership of 12,254,080, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 7,964,345 shares of the stock with an approximate value of $0.69 million in ZOM stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $86000.0 in ZOM stock with ownership of nearly New of the company’s market capitalization.
Positions in Zomedica Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 19 institutional holders increased their position in Zomedica Corp. [AMEX:ZOM] by around 12,219,748 shares. Additionally, 2 investors decreased positions by around 30,700 shares, while 7 investors held positions by with 12,658,451 shares. The mentioned changes placed institutional holdings at 24,908,899 shares, according to the latest SEC report filing. ZOM stock had 14 new institutional investments in for a total of 3,986,124 shares, while 2 institutional investors sold positions of 30,700 shares during the same period.